TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01290783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irintoecan
Description: * Irinotecan, 180 mg/m2 IV, over 90 minutes, day 1 (in patients \> 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).~* Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.~* 5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.~* Repeat every two weeks.~* 8 months of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA-Irinotecan solution for Infusion
Description: * HA-Irinotecan (irinotecan 180 mg/m2), IV, over 90 minutes, day 1 (in patients \> 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).~* Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.~* 5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.~* Repeat every two weeks~* 8 months of treatment.
Study: NCT00741351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane + Fentanyl
Description: Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and fentanyl (2-3 microg/kg/hr or 0.7 microg/kg boluses). Just before incision of the scalp, fentanyl (1-2microg/kg/hr) can be supplemented, if necessary

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane + Remifentanyl
Description: Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and remifentanil (0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening). Just before incision of the scalp, remifentanil can be supplemented, if necessary

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol + Remifentanyl
Description: Propofol is maintained with continuous infusion at 10 mg/kg/h for the first 10 minutes, then reduced to 8 mg/kg/h for the following 10 minutes and reduced to 6mg/kg/h thereafter and remifentanil 0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening. Just before incision of the scalp, remifentanil could be supplemented, if necessary
Study: NCT02640222

Intervention type: DRUG
Intervention: VKA

Intervention type: DRUG
Intervention: VKA
Study: NCT02640222

Intervention type: DRUG
Intervention: Apixaban

Intervention type: DRUG
Intervention: Apixaban

Intervention type: DRUG
Intervention: dabigatran

Intervention type: DRUG
Intervention: dabigatran

Intervention type: DRUG
Intervention: rivaroxaban

Intervention type: DRUG
Intervention: rivaroxaban
Study: NCT03212950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fast-CL
Description: After the admission we will insert new insulin (blinded) into the insulin pump. At 13:00 they will have lunch (with manual bolus). At 15:00 we will start CL control, participants/investigators will not be allowed to deliver manual bolus till the end of the study period. All meals and afternoon exercise (in the time between 16:30 and 19:30) will be unannounced and managed with CL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular-CL
Description: After the admission we will insert new insulin (blinded) into the insulin pump. At 13:00 they will have lunch (with manual bolus). At 15:00 we will start CL control, participants/investigators will not be allowed to deliver manual bolus till the end of the study period. All meals and afternoon exercise (in the time between 16:30 and 19:30) will be unannounced and managed with CL.
Study: NCT02692287

Intervention type: DEVICE
Group type: OTHER
Intervention: The PPH Butterfly
Description: The PPH Butterfly is a simple, low cost device that has been developed to facilitate less invasive compression of the uterus in a PPH
Study: NCT02786290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenflow Spring System
Description: The Zenflow Spring is a nitinol urethral implant for the treatment of Lower Urinary Tract Symptoms (LUTS) that arise due to bladder outlet obstruction (BOO), secondary to the presence of Benign Prostatic Hypertrophy (BPH). The device is intended to be a permanent implant however it may be removed if necessary.
Study: NCT03553485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulation
Description: The transcutaneous auricular vagus nerve stimulator Parasym consists of a stimulation unit and a dedicated ear electrode. The stimulation unit, having approximately the size of a common mobile phone, sends out the electrical impulses. It is connected with the ear electrode, which patients wear like an earphone. The patient can regulate and adapt the intensity of the stimulation (current intensity) according to his/her individual sensitivity, which can vary from day to day or even over the period of the therapy.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham Earclip electrodes are electrodes that appear identical to functioning electrodes, however do not deliver any stimulation due to removed wiring.

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Radiotherapy
Description: Standard treatment for included patients

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Standard treatment for included patients
Study: NCT02539134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-935 placebo-matching oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-935 placebo-matching oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-935 placebo-matching oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-935 placebo-matching oral solution
Study: NCT05202275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Intensity-modulated radiotherapy was given to the patients with regimen of 69.96 Gy-73.92 Gy to the gross target volume of nasopharynx, 69.96 Gy to the gross target volume of positive nodes, 60.06 Gy the high risk clinical target volume, 50.96 Gy to the low risk clinical target volume. Concurrent chemotherapy is administrated with cisplatin 100mg/m2 at d1, d22, d43 during radiotherapy. All patients were given orally olanzapine 10mg once on d1-5; intravenously palonosetron 0.25mg once on d1; aprepitant 125 mg once on d1, then 80mg once on d2-5 at every chemotherapy cycle.
Study: NCT00396877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel (SR25990)
Description: Form: reconstituted solution using Clopidogrel powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Form: reconstituted solution using matching placebo powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight
Study: NCT04060199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viltolarsen
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study: NCT03738449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-387
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-387
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D484
Description: reference drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D484
Description: reference drug
Study: NCT02259634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Motivational Interviewing
Study: NCT01093651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 100 mg sitagliptin daily for 4-6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily placebo for 4-6 months
Study: NCT01752868

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement
Description: Participants in this group will take the following nutritional supplements on a daily basis: curcumin, fish oil, resveratrol, sesamin, Acetyl-L-carnitine, lipoic acid, green and black teas, quercetin, pomegranate, cinnamon bark.
Study: NCT00376272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02984267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Using ultrasound guidance to evaluate the spine prior to epidural placement
Study: NCT04402203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Favipiravir 200 mg (Favipira) tablet will be given orally. Day 1: Tablet Favipiravir 1600 mg twice daily Days 2-Days 10: Tablet Favipiravir 600 mg twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Only Standard Treatment
Description: Standard treatment included oxygen inhalation, oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs \& the medication any patient is on due to any concomitant diseases.
Study: NCT02496143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: EC-18 will be supplied as 500 mg Softgel capsules. The study will include up to four sequential dose cohorts. Six subjects in each cohort will be randomized to receive EC-18: 500, 1000, 2000, or 4000 mg by oral administration of 1, 2, 4, and 8 EC-18 capsules, for Cohorts 1, 2, 3 or 4, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: EC-18 will be supplied as 500 mg Softgel capsules. The study will include up to four sequential dose cohorts. Six subjects in each cohort will be randomized to receive EC-18: 500, 1000, 2000, or 4000 mg by oral administration of 1, 2, 4, and 8 EC-18 capsules, for Cohorts 1, 2, 3 or 4, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: EC-18 will be supplied as 500 mg Softgel capsules. The study will include up to four sequential dose cohorts. Six subjects in each cohort will be randomized to receive EC-18: 500, 1000, 2000, or 4000 mg by oral administration of 1, 2, 4, and 8 EC-18 capsules, for Cohorts 1, 2, 3 or 4, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: EC-18 will be supplied as 500 mg Softgel capsules. The study will include up to four sequential dose cohorts. Six subjects in each cohort will be randomized to receive EC-18: 500, 1000, 2000, or 4000 mg by oral administration of 1, 2, 4, and 8 EC-18 capsules, for Cohorts 1, 2, 3 or 4, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as Softgel capsules. The study will include up to four sequential dose cohorts. Two subjects in each cohort will be randomized to placebo and will receive 1, 2, 4 or 8 placebo capsules for Cohorts 1, 2, 3 or 4, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as Softgel capsules. The study will include up to four sequential dose cohorts. Two subjects in each cohort will be randomized to placebo and will receive 1, 2, 4 or 8 placebo capsules for Cohorts 1, 2, 3 or 4, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as Softgel capsules. The study will include up to four sequential dose cohorts. Two subjects in each cohort will be randomized to placebo and will receive 1, 2, 4 or 8 placebo capsules for Cohorts 1, 2, 3 or 4, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as Softgel capsules. The study will include up to four sequential dose cohorts. Two subjects in each cohort will be randomized to placebo and will receive 1, 2, 4 or 8 placebo capsules for Cohorts 1, 2, 3 or 4, respectively.
Study: NCT01349036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: Capsules administered once or twice daily, continuous dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: Capsules administered once or twice daily, continuous dosing
Study: NCT01182207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone/Ethinyl Estradiol (Gianvi®)
Description: 3 mg/0.02 mg Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YAZ®
Description: 3 mg/0.02 mg Tablets
Study: NCT01907022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left DLPFC Butterfly Coil
Description: High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold. Relaxation therapy during the 1Hz stimulation with external audio tape instructions.~Arms: Left DLPFC Butterfly Coil
Study: NCT01087814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Subject will take efavirenz for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Over-encapsulated efavirenz
Description: Subject will take efavirenz that has been over-encapsulated with a gel capsule for 5 days.
Study: NCT04089839

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT03987464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planning for the Future
Description: This intervention will include attending an advance directives meeting, a living arrangements workshop, and a psychosocial education training workshop.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Medical Engagement
Description: This intervention includes creating a health portfolio, health record access training, and a medical engagement workshop

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Confidence Building and Social Engagement
Description: This intervention includes mindfulness training, a pre-experience training techniques workshop and a memory strategies class.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Intervention
Description: This intervention includes physical/occupational therapy (PT/OT), a home safety assessment, and an independent exercise program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Adherence
Description: This intervention includes using automated pillboxes to ensure medication compliance, optimizing appropriate medication use through review, and engaging with memory medications via class.
Study: NCT01919398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940680
Description: Administered orally
Study: NCT01137877

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Milk based infant formula powder
Description: milk based infant formula ad lib

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational Infant Formula #1
Description: Milk based infant formula ad lib

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational Infant Formula #2
Description: Milk based infant formula powder ad lib

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Human Milk
Description: Human milk ad lib
Study: NCT01077011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lubricant eye drop FID 115958D
Description: 1 drop in each eye, one time

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GenTeal Gel
Description: 1 drop in each eye, one time
Study: NCT04662606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consumption of a standard meal prior to the fMRI data collection
Description: Consumption of a standard meal prior to the fMRI data collection
Study: NCT00488319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: 1.5 to 12 mg tablet once daily for 6 months
Study: NCT04255173

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Body mass index
Description: Body mass index is calculated as a ratio of height and weight, expressed as kg/m2

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: waist circumference
Description: waist circumference is measured as cm

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: hip circumference
Description: hip circumference is measured as cm

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: height
Description: height is measured as cm

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fat percentage
Description: Fat percentage and skeletal muscle mass (SMM) was calculated by using bioimpedance analysis (BIA) (Tanita TBF 300; Tanita Corp., Tokyo, Japan).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Skeletal muscle index
Description: Skeletal muscle index (SMI) was calculated from BIA-based skeletal muscle mass with a formula as SMM/height \[m2\].

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: A body shape index (ABSI)
Description: ABSI is measured as waist circumference (m) / (BMI(kg)2/3x Height(m)5/6)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dual energy x ray absorptiometry (DXA)
Description: Osteoporosis is diagnosed with DXA scores. According to the T-scores calculated from femur neck (FN) and lumbar spine (LS), subjects divided into 3 groups as following: a) normal: T-score is greater than -1 SD (standard deviation), b) osteopenia: T-score is between -1 and -2.5 SD, c) osteoporosis: T-score is lower than -2.5 SD.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The Rapid Assessment of Physical Activity (RAPA) aerobic assessment
Description: Physical activity levels of patients were evaluated with The Rapid Assessment of Physical Activity (RAPA) aerobic assessment. Patients divided into 5 groups as following: 1 = sedentary, 2 = underactive, 3 = regular underactive (light activities), 4 = regular underactive, and 5 = regular active).
Study: NCT02360813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Description: Fifty-six sessions of principle driven cognitive remediation therapy. Three individual sessions and one group session each week for approximately fourteen weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Keep getting usual care.
Study: NCT03799289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss followed by yoga instruction
Description: 12-week standard behavioral weight loss program followed by a 12-week yoga intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral weight loss followed by cooking/dietary education instruction
Description: 12-week standard behavioral weight loss program followed by a 12-week cooking/dietary education intervention
Study: NCT00806598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 3.5 or 2.5 mg/kg/day IV for 5 days~* Aplastic anemia patients receive 3.5 mg/kg/day for 5 days~* MDS patients \<55 years receive 3.5 mg/kg/day for 5 days~* MDS patients \>55 years receive 2.5 mg/kg/day for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: 5 mg/kg orally for 6 months; start after completing thymoglobulin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 1 mg/kg/day IV for 5 days, given before each dose of thymoglobulin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 microgram/kg subcutaneously daily up to 3 months, start after thymoglobulin.
Study: NCT04343859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMMH-010
Description: After tolerance study, 360mg and above IMMH-010 will be administered in Dose expansion study.
Study: NCT01726517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT02606097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Study: NCT03705533

Intervention type: DRUG
Group type: OTHER
Intervention: Telmisartan
Description: Telmisartan is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 80 mg of telmisartan.

Intervention type: DRUG
Group type: OTHER
Intervention: Telmisartan
Description: Telmisartan is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 80 mg of telmisartan.

Intervention type: DRUG
Group type: OTHER
Intervention: Micardis
Description: Micardis is manufactured by Boehringer Ingelheim Ellas AE, Greece. Each tablet contains 80 mg of telmisartan.
Study: NCT02984267

Intervention type: OTHER
Group type: OTHER
Intervention: Palpation
Description: Using palpation only to evaluate the spine prior to epidural placement
Study: NCT01110213

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Participants received two individually tailored phone calls and two condition specific newsletters encouraging goal setting and weighing the pros and cons for physical activity.
Study: NCT03705533

Intervention type: DRUG
Group type: OTHER
Intervention: Micardis
Description: Micardis is manufactured by Boehringer Ingelheim Ellas AE, Greece. Each tablet contains 80 mg of telmisartan.
Study: NCT01705145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Study: NCT02269917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF
Description: Once-daily single-tablet regimen containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Boosted Protease Inhibitor (bPI)
Description: Boosted protease inhibitor (limited to darunavir \[DRV\] or atazanavir with low-dose ritonavir \[rtv\] or cobicistat \[COBI\], or lopinavir with rtv) as per current treatment regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF).
Study: NCT01110213

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable
Description: Participants received two individually tailored phone calls and two condition specific newsletters encouraging goal setting and weighing the pros and cons for fruit and vegetable consumption.